A good overview on current methods of assessing liver damage by Dr. Scott Friedman of NY's Mount Sinai Hospital. Dr. Friedman specializes in in liver Fibrosis issues. Free registration to the Clinical Options site is required: http://tinyurl.com/38onph
Conclusion:
The development of accurate, noninvasive markers of liver fibrosis has become an urgent priority in order to allow the evaluation of antifibrotic and antiviral drugs in clinical trials. Interest is accelerating in new modalities, as well as in refining existing methods including serum assays, elastography, proteomics, and imaging techniques (ultrasound, CT, and MRI).
One proposed diagnostic algorithm includes the use of non-invasive markers initially, followed by an assessment with liver biopsy where results are ambiguous or the diagnosis is in doubt.
Complete module here: http://tinyurl.com/38onph